The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
126504971 12650497 1 I 20160724 20160725 20160815 20160815 EXP GB-ROCHE-1801652 ROCHE 54.04 YR F Y 65.20000 KG 20160815 MD GB GB

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
126504971 12650497 1 SS PACLITAXEL. PACLITAXEL 1 Intravenous (not otherwise specified) DATE OF MOST RECENT DOSE PRIOR TO PYREXIA ONSET: 20/JUL/2016 OF 138 MG?DATE OF MOST RECENT DOSE PRIO 1149736,1148073 0 80 MG/M**2
126504971 12650497 2 C ERYTHROMYCIN. ERYTHROMYCIN 1 Oral 0 250 MG
126504971 12650497 3 C THYROXINE LEVOTHYROXINE 1 Oral 0 75 UG
126504971 12650497 4 C OMEPRAZOLE. OMEPRAZOLE 1 Oral 0 20 MG
126504971 12650497 5 C OMEPRAZOLE. OMEPRAZOLE 1 0
126504971 12650497 6 C DOXYCYCLINE. DOXYCYCLINE 1 Oral 0 100 MG
126504971 12650497 7 C DOXYCYCLINE. DOXYCYCLINE 1 Oral 0 100 MG
126504971 12650497 8 C BACTROBAN MUPIROCINMUPIROCIN CALCIUM 1 Topical 0 2 PCT
126504971 12650497 9 C BACTROBAN MUPIROCINMUPIROCIN CALCIUM 1 Topical 0 2 PCT
126504971 12650497 10 C OCTENISAN (ALLANTOIN/OCTENIDINE HYDROCHLORIDE) 2 Topical 0 10 ML
126504971 12650497 11 C OCTENISAN (ALLANTOIN/OCTENIDINE HYDROCHLORIDE) 2 Topical 0 10 ML
126504971 12650497 12 C FERROUS SULFATE. FERROUS SULFATE 1 Oral 0 200 MG
126504971 12650497 13 C MEROPENEM. MEROPENEM 1 Intravenous (not otherwise specified) 0 1000 MG
126504971 12650497 14 C PACKED RED CELLS 2 Intravenous (not otherwise specified) 0 2 IU
126504971 12650497 15 C ARANESP DARBEPOETIN ALFA 1 Subcutaneous 0 500 UG
126504971 12650497 16 PS Cobimetinib COBIMETINIB 1 Oral DATE OF MOST RECENT DOSE PRIOR TO PYREXIA ONSET: 24/JUL/2016, 60 MG?DATE OF MOST RECENT DOSE PRIOR T Y ANQ09080 206192

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
126504971 12650497 1 Breast cancer metastatic
126504971 12650497 2 Prophylaxis
126504971 12650497 3 Hypothyroidism
126504971 12650497 4 Dyspepsia
126504971 12650497 5 Dyspepsia
126504971 12650497 6 Infection
126504971 12650497 8 Staphylococcal infection
126504971 12650497 10 Staphylococcal infection
126504971 12650497 12 Anaemia
126504971 12650497 13 Infection
126504971 12650497 14 Anaemia
126504971 12650497 15 Anaemia
126504971 12650497 16 Breast cancer metastatic

Outcome of event

Event ID CASEID OUTC COD
126504971 12650497 HO

Reactions reported

Event ID CASEID DRUG REC ACT PT
126504971 12650497 Dyspnoea
126504971 12650497 Pyrexia

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
126504971 12650497 1 20160621 0
126504971 12650497 2 198105 0
126504971 12650497 3 1991 0
126504971 12650497 4 2011 0
126504971 12650497 6 20160712 20160716 0
126504971 12650497 7 20160803 0
126504971 12650497 8 20160713 20160718 0
126504971 12650497 9 20160802 20160802 0
126504971 12650497 10 20160713 20160718 0
126504971 12650497 11 20160802 20160804 0
126504971 12650497 12 20160720 0
126504971 12650497 13 20160802 20160803 0
126504971 12650497 14 20160804 20160804 0
126504971 12650497 15 20160803 0
126504971 12650497 16 20160623 0